Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 10,356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

NCT04212169
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MEDI3506, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 6, 2026, 5:31 AM EST
Completed Not applicable Interventional

Patient-Empowered Mobile Technology in Hospitalized Patients (TRU-PAIN)

NCT02895841
View directory record Official record
Conditions
Pain
Interventions
SMART app wearable
Other
Lead sponsor
Duke University
Other
Eligibility
8 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Nov 6, 2026, 5:31 AM EST
Terminated Phase 4 Interventional Results available

INdividualized ITI Based on Fviii(ATE) Protection by VWF

NCT03204539
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia A
Interventions
Wilate
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Sacramento, California • San Diego, California • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Nov 6, 2026, 5:31 AM EST
Completed Phase 3 Interventional Results available

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome

NCT03649477
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin, placebo
Drug
Lead sponsor
Levo Therapeutics, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 6, 2026, 5:31 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 6, 2026, 5:31 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

NCT03048279
View directory record Official record
Conditions
Multiple Endocrine Neoplasia Syndromes
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 6, 2026, 5:31 AM EST
Recruiting Phase 1 Interventional

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

NCT07901959
View directory record Official record
Conditions
Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions
Metformin, Naproxen Sodium
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 6, 2026, 5:31 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

NCT00316459
View directory record Official record
Conditions
Healthy, Long QT Syndrome
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2007 · Synced Nov 6, 2026, 5:31 AM EST
Completed Phase 2 Interventional Results available

Prasugrel Versus Placebo in Adult Sickle Cell Disease

NCT01167023
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Nov 6, 2026, 5:31 AM EST
Completed Phase 2 Interventional

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

NCT04504279
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB-401, Placebo
Biological
Lead sponsor
Forte Biosciences, Inc.
Industry
Eligibility
2 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Fremont, California • Lake City, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 6, 2026, 5:31 AM EST
Completed No phase listed Observational

A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

NCT04255680
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Buccal Swabs and Blood Draws
Diagnostic Test
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
20 participants
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Nov 6, 2026, 5:31 AM EST
Withdrawn Phase 2 Interventional

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

NCT01832896
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Ecallantide subcutaneous dosing
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Nov 6, 2026, 5:31 AM EST
Active, not recruiting No phase listed Observational

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

NCT05568459
View directory record Official record
Conditions
Hemophilia B
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
16 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 6, 2026, 5:31 AM EST
Active, not recruiting No phase listed Observational

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

NCT02698579
View directory record Official record
Conditions
Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Interventions
No interventional drug product utilized in this follow-up study
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
Up to 19 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2038
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 6, 2026, 5:31 AM EST
Completed No phase listed Observational

MENstrual Symptom Tracking to Understand and Assess (Women) Living With Cystic Fibrosis

NCT04620096
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Nov 6, 2026, 5:31 AM EST
Recruiting No phase listed Observational

Modifiable Variables in Parkinsonism (MVP)

NCT02194816
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
19 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Nov 6, 2026, 5:31 AM EST
Terminated Phase 3 Interventional

A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

NCT01749306
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
ABH001, Control wound treatment
Biological · Other
Lead sponsor
Shire Regenerative Medicine, Inc.
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Phoenix, Arizona • Redwood City, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Nov 6, 2026, 5:31 AM EST
Completed Phase 1 Interventional Results available

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

NCT03664804
View directory record Official record
Conditions
Huntington's Disease
Interventions
No Study Drug was Administered in this Study
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Englewood, Colorado • Washington D.C., District of Columbia • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Nov 6, 2026, 5:31 AM EST
Completed No phase listed Observational

Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease

NCT01707433
View directory record Official record
Conditions
Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI
Interventions
Enzyme testing
Other
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Nov 6, 2026, 5:31 AM EST
Completed Not applicable Interventional

Body Weight Support Harness System in Spinal Muscular Atrophy

NCT05715749
View directory record Official record
Conditions
Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
Interventions
In-home body weight support harness system
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Nov 6, 2026, 5:31 AM EST
Completed Phase 2 Interventional

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

NCT00357084
View directory record Official record
Conditions
Cancer
Interventions
methotrexate, methylprednisolone, prednisone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Nov 6, 2026, 5:31 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Mirtazapine and Methamphetamine Drug-drug Interaction Study

NCT04614584
View directory record Official record
Conditions
Methamphetamine Use Disorder, Drug Interaction, Cardiovascular Abnormalities
Interventions
Mirtazapine, Methamphetamine
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Nov 6, 2026, 5:31 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

Gene Therapy Trial for CLN6 Batten Disease

NCT07582484
View directory record Official record
Conditions
CLN6, Batten Disease, Batten's Disease, Neuronal Ceroid Lipofuscinosis CLN6, Neuronal Ceroid Lipofuscinosis
Interventions
scAAV9.CB.CLN6 (dose: 1.5E14 vector genomes)
Drug
Lead sponsor
The Charlotte and Gwenyth Gray Foundation
Other
Eligibility
4 Months and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 6, 2026, 5:31 AM EST
Recruiting Phase 2 Interventional

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

NCT06541847
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
HLX-1502
Drug
Lead sponsor
Healx Limited
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 6, 2026, 5:31 AM EST